Clinical trial
A Phase IIB, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Sutezolid in Combination With Bedaquiline, Delamanid and Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis
NCT03959566 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIB, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Sutezolid in Combination With Bedaquiline, Delamanid and Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis
- Lead sponsor
- Michael Hoelscher
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 6, 2021
- Completion date
- September 30, 2022
- Enrollment
- 75 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
other specified pulmonary tuberculosis, pulmonary tuberculosis